Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| UNITED THERAPEUTICS CorpUTHR · Entity 664 | EVP & GENERAL COUNSEL | October 01, 2026 | October 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
UNITED THERAPEUTICS Corp
Report date October 01, 2026 · Filed October 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 45,172 |
Ending reported balance
After 2026-10-01 transaction · row 11
11 source rows · reconciled sequenceRow 1 · 2026-10-01 · Exercise / conversion · Acquired 8,300 · Balance 53,472 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Row 2 · 2026-10-01 · Sale · Disposed 880 · Balance 52,592 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-10-01 · Sale · Disposed 1,480 · Balance 51,112 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-10-01 · Sale · Disposed 780 · Balance 50,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-10-01 · Sale · Disposed 1,480 · Balance 48,852 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 6 · 2026-10-01 · Sale · Disposed 400 · Balance 48,452 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 7 · 2026-10-01 · Sale · Disposed 720 · Balance 47,732 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 8 · 2026-10-01 · Sale · Disposed 739 · Balance 46,993 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 9 · 2026-10-01 · Sale · Disposed 838 · Balance 46,155 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 10 · 2026-10-01 · Sale · Disposed 823 · Balance 45,332 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 11 · 2026-10-01 · Sale · Disposed 160 · Balance 45,172 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $146.03 · Expires 2027-03-15 | Direct | 39,240 |
Reported balance
After 2026-10-01 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2026-10-01 · Exercise / conversion · Disposed 8,300 · Balance 39,240 F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. |
Filing footnotes · ownership attribution and instrument terms
F1: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025.
F2: This transaction was executed in multiple trades at prices ranging from $558.30 to $558.31. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $560.00 to $560.50. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $561.70 to $562.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: This transaction was executed in multiple trades at prices ranging from $562.80 to $563.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F6: This transaction was executed in multiple trades at prices ranging from $566.405 to $566.41. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F7: This transaction was executed in multiple trades at prices ranging from $567.495 to $568.175. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F8: This transaction was executed in multiple trades at prices ranging from $568.94 to $569.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F9: This transaction was executed in multiple trades at prices ranging from $570.405 to $571.32. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F10: This transaction was executed in multiple trades at prices ranging from $571.48 to $572.45. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 360 | $518.82 | $186,776.32 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,800 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $518.735 to $519.13. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 780 | $517.94 | $403,994.06 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,160 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $517.53 to $518.18. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,617 | $516.93 | $835,868.86 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,940 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $516.52 to $517.33. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,360 | $515.93 | $701,665.21 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,557 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $515.50 to $516.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,795 | $514.82 | $924,106.03 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,917 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $514.47 to $515.335. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 760 | $512.92 | $389,817.22 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,712 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $512.67 to $513.61. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 06, 2026 Filed Aug 6, 2026 20:35 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,300 | $146.03 | $1,212,049.00 |
DisclosureSEC source: 0001231589-26-000017 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 8,300 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · derivative · entry 10 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 80,740 Underlying: Common Stock · 8,300 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 80 | $536.85 | $42,948.21 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,172 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $536.75 to $536.93. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,519 | $534.99 | $812,648.44 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,252 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $534.56 to $535.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,041 | $535.88 | $557,850.87 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,771 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $535.565 to $536.54. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 3,279 | $534.21 | $1,751,679.18 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,812 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $533.56 to $534.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 800 | $532.94 | $426,351.52 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,091 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $532.51 to $533.47. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 861 | $531.97 | $458,025.48 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,891 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $531.50 to $532.42. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 120 | $529.81 | $63,577.20 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,752 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 600 | $527.60 | $316,557.00 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,872 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 16, 2026 Filed Jul 16, 2026 20:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,300 | $146.03 | $1,212,049.00 |
DisclosureSEC source: 0001231589-26-000016 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 8,300 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · derivative · entry 11 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 89,040 Underlying: Common Stock · 8,300 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 225 | $556.36 | $125,180.75 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 10 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,172 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $556.19 to $556.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 990 | $555.83 | $550,267.44 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,397 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $555.16 to $556.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 299 | $554.45 | $165,779.17 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,387 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $554.13 to $555.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,201 | $553.52 | $1,218,290.26 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,686 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $553.13 to $554.10. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,818 | $552.61 | $1,004,639.16 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,887 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $552.12 to $553.11. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,467 | $551.30 | $808,751.38 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,705 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $550.85 to $551.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 384 | $550.02 | $211,209.02 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,172 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $549.535 to $550.38. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 258 | $548.73 | $141,572.70 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,556 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $548.47 to $549.27. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 658 | $548.00 | $360,584.79 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,814 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $547.45 to $548.43. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 02, 2026 Filed Jul 2, 2026 20:32 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,300 | $146.03 | $1,212,049.00 |
DisclosureSEC source: 0001231589-26-000015 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 8,300 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · derivative · entry 13 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,340 Underlying: Common Stock · 8,300 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 400 | $551.74 | $220,696.00 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 12 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,172 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F11 · price: This transaction was executed in multiple trades at prices ranging from $551.50 to $551.98. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 496 | $548.91 | $272,260.60 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 11 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,572 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F10 · price: This transaction was executed in multiple trades at prices ranging from $548.415 to $549.165. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 881 | $547.65 | $482,475.95 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 10 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,068 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F9 · price: This transaction was executed in multiple trades at prices ranging from $547.13 to $547.945. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 157 | $546.15 | $85,744.89 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,949 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F8 · price: This transaction was executed in multiple trades at prices ranging from $545.88 to $546.39. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 480 | $544.26 | $261,246.29 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,106 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $544.215 to $545.16. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 160 | $541.95 | $86,712.00 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,586 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 950 | $541.26 | $514,192.25 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,746 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $540.87 to $541.85. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 798 | $540.25 | $431,118.46 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,696 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $539.865 to $540.84. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,305 | $539.42 | $703,937.10 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,494 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $538.86 to $539.79. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 958 | $538.03 | $515,430.54 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 50,799 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $537.58 to $538.55. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,715 | $537.04 | $921,026.69 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 51,757 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $536.495 to $537.46. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 18, 2026 Filed Jun 18, 2026 20:31 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionCommon Stock | 8,300 | $146.03 | $1,212,049.00 |
DisclosureSEC source: 0001231589-26-000014 · primarydocument.xml · nonDerivative · entry 1 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,472 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | Exercise / conversionStock Option · Derivative | 8,300 | $0.00 Strike: $146.03 | $0.00 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · derivative · entry 10 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 105,640 Underlying: Common Stock · 8,300 shares Expires 2027-03-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,250 | $549.47 | $686,837.50 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 9 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 45,172 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 593 | $549.49 | $325,850.42 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 8 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,422 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F7 · price: This transaction was executed in multiple trades at prices ranging from $549.12 to $549.80. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 1,481 | $548.43 | $812,217.43 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 7 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 47,015 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F6 · price: This transaction was executed in multiple trades at prices ranging from $547.90 to $548.88. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 935 | $547.11 | $511,548.60 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 6 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 48,496 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F5 · price: This transaction was executed in multiple trades at prices ranging from $546.80 to $547.75. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 2,627 | $546.42 | $1,435,439.56 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 5 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,431 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F4 · price: This transaction was executed in multiple trades at prices ranging from $545.80 to $546.72. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 374 | $545.27 | $203,929.90 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 4 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,058 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F3 · price: This transaction was executed in multiple trades at prices ranging from $544.795 to $545.77. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 840 | $543.89 | $456,867.01 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 3 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,432 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. F2 · price: This transaction was executed in multiple trades at prices ranging from $543.59 to $544.03. The price reported above reflects the weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 04, 2026 Filed Jun 4, 2026 21:30 UTC | UNITED THERAPEUTICS Corp UTHR · Entity 664 | SaleCommon Stock | 200 | $539.76 | $107,952.00 |
DisclosureSEC source: 0001231589-26-000013 · primarydocument.xml · nonDerivative · entry 2 MAHON PAUL A · CIK 0001231589 · EVP & GENERAL COUNSEL 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 53,272 F1 · kind: This is an exercise of stock options and sale of the resulting shares pursuant to a pre-arranged 10b5-1 plan entered into by the reporting person on August 11, 2025. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.